Celularity announced that it will present in vitro data from its investigational natural killer NK cell therapy programs at this year’s American Society of Gene and Cell Therapy ASGCT Annual Meeting. The preclinical data, which suggest that Celularity’s placenta-derived unmodified natural killer NK cells CYNK-001 and genetically modified NK cells CYNK-201 may serve as potent and selective senolytic agents for use in addressing age-related diseases, will be presented on May 9. “Celularity believes in the broad, but so far underrealized, potential of cell therapies. We continue to investigate cellular immunotherapy in age-related diseases, and these data are an important, continued step in demonstrating how our therapeutic assets may be used to eliminate senescent cells,” said Celularity’s CEO and Founder Dr. Robert Hariri, M.D., Ph.D. “Removing these aging, senescent cells, which we have termed ‘senoablation,’ may represent an important clinical approach to address the high societal cost of age-associated diseases and disabilities.” The ASGCT Annual Meeting will take place on May 7 through 11 in Baltimore, Md.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELU:
- Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
- Celularity receives HCPCS Q code approval from U.S. CMS for Biovance 3L
- Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
- Celularity submits request to FDA for orphan drug designation for PDA-002
- Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit
